Envelope Facebook-f Linkedin
GET IN TOUCH

Acurion Rebrands and Innovates in Precision Oncology

Helpful Information About TBI’s

Additional Case Management information:

News Summary

Acurion, formerly known as io9, reveals its new identity amid a mission to transform precision oncology. With the introduction of OncoGaze™, an AI platform for rapid genomic analysis, Acurion aims to expedite cancer treatment. Supported by a strong leadership team, the company plans to enhance precision medicine accessibility and launch a Series A fundraising in 2025 to finance its growth initiatives.

Acurion Unveils New Identity While Shaping the Future of Precision Oncology

In an exciting development for the world of cancer treatment, a company formerly known as io9 has officially rebranded itself as Acurion. This change is more than just a new name; it’s part of a broader plan to align with the company’s changing mission and future aspirations.

Acurion is setting its sights on making waves in the field of precision oncology — the approach that tailors cancer treatment based on the individual characteristics of each patient’s cancer. With this new identity, Acurion has also put an impressive leadership team in place, tasked with guiding the company into its next chapter of growth.

The Vision Behind the Change

At the heart of Acurion’s mission is a strong commitment to making precision medicine more accessible to cancer patients. The company is determined to cut down on the often long and confusing waiting times between diagnosis and the start of effective therapies. Currently, many cancer patients face costly delays that can hinder their treatment paths. Acurion’s innovative approach aims to speed up the entire process.

OncoGaze™: The Game-Changer

One of Acurion’s standout offerings, OncoGaze™, is an artificial intelligence platform that has recently gained attention, even being featured on CNN’s Global Innovations. This cutting-edge technology allows for an incredibly fast identification of genomic biomarkers from tumor biopsy slides, reducing the time for initiating first-line treatment from several weeks to mere seconds. The goal is clear: to make precision therapies available not just locally, but on a global scale for those in need.

What sets OncoGaze apart is its accuracy. This platform stands out as being more precise than traditional FDA-approved genomic testing and has even been published in the esteemed Journal of Clinical Oncology. Its growing support from the oncology community further highlights its potential to transform cancer care.

Leadership Team Taking the Helm

Acurion’s ambitious plans are backed by a talented leadership team, each member bringing a wealth of experience from different corners of the healthcare industry. At the helm is Rick Fultz, the new Chief Executive Officer, who has spent over 15 years leading growth in the life sciences sector. Alongside him, Feng Cao, Ph.D., takes on the role of Chief Operating Officer, focusing on operational management and regulatory strategies.

The scientific backbone of Acurion is provided by Ludmil Alexandrov, Ph.D., the Chief Scientific Officer, recognized for his expertise in cancer genomics, and Erik Bergstrom, Ph.D., Chief Technology Officer, who has a rich history in computational biology and artificial intelligence. Rounding out the leadership team is Shelly Vandertie, the Vice President of Finance, overseeing the company’s financial strategy and operations.

Looking Ahead: Fundraising for Growth

With big dreams on the horizon, Acurion is preparing to launch its Series A fundraising on April 15, 2025. The funds raised will be crucial in supporting ongoing growth and innovation efforts, bolstering the company’s goal to change frontline cancer care.

Acurion is not tackling this massive endeavor alone. The company is collaborating with research institutions, patient advocacy groups, and industry leaders to enhance precision oncology and provide oncologists with essential genomic insights, speeding up the treatment process for cancer patients.

As Acurion embarks on this exciting new journey, their commitment to transforming cancer care and making precision oncology more accessible is clear. By harnessing the power of advanced technology and innovative thinking, they are poised to make a significant impact in the lives of many individuals battling cancer.

Deeper Dive: News & Info About This Topic

Additional Resources